The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.
Immunogen design for HIV-1 vaccines could be based on epitope identification of naturally occurring neutralizing antibodies in infected patients. A tier 2 neutralizing monoclonal antibody (mAb), HJ16 recognizes a new epitope in the CD4 binding site (CD4bs) region that only partially overlaps with th...
Enregistré dans:
Auteurs principaux: | Sunita S Balla-Jhagjhoorsingh, Davide Corti, Leo Heyndrickx, Elisabeth Willems, Katleen Vereecken, David Davis, Guido Vanham |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7f92aeb3878d4fa3843e47aaabbfeeb0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Global site-specific N-glycosylation analysis of HIV envelope glycoprotein
par: Liwei Cao, et autres
Publié: (2017) -
Alterations in protein expression and site-specific N-glycosylation of prostate cancer tissues
par: Simon Sugár, et autres
Publié: (2021) -
Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies
par: Christopher A. Cottrell, et autres
Publié: (2021) -
Site-specific N-glycosylation analysis of animal cell culture-derived Zika virus proteins
par: Alexander Pralow, et autres
Publié: (2021) -
Acta Nº276
par: Banco Central de Chile
Publié: (2019)